Research ArticleDrug Discovery and Translational Medicine
Parallel Buprenorphine phMRI Responses in Conscious Rodents and Healthy Human Subjects
Lino Becerra, Jaymin Upadhyay, Pei-Ching Chang, James Bishop, Julie Anderson, Richard Baumgartner, Adam J. Schwarz, Alexandre Coimbra, Diana Wallin, Lauren Nutile, Edward George, Gary Maier, Soujanya Sunkaraneni, Smriti Iyengar, Jeffrey L. Evelhoch, David Bleakman, Richard Hargreaves and David Borsook
Journal of Pharmacology and Experimental Therapeutics April 2013, 345 (1) 41-51; DOI: https://doi.org/10.1124/jpet.112.201145
Lino Becerra
Imaging Consortium for Drug Development (L.B., J.U., P.-C.C., J.B., J.A., R.B., A.J.S., A.C., D.W., L.N., E.G., G.M., S.S., S.I., J.L.E., D.B., R.H., D.B.), P.A.I.N. Group, Children’s Hospital of Boston, Waltham, Massachusetts (L.B., J.U., P.-C.C., J.B., J.A., D.W., L.N., E.G., D.B.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (L.B., D.B.); Merck Research Laboratories, Merck and Company, West Point, Pennsylvania (R.B., A.C., J.L.E., R.H.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (A.J.S., S.I., D.B.); and Sunovion Inc., Marlborough, Massachusetts (S.S., G.M.)
Jaymin Upadhyay
Imaging Consortium for Drug Development (L.B., J.U., P.-C.C., J.B., J.A., R.B., A.J.S., A.C., D.W., L.N., E.G., G.M., S.S., S.I., J.L.E., D.B., R.H., D.B.), P.A.I.N. Group, Children’s Hospital of Boston, Waltham, Massachusetts (L.B., J.U., P.-C.C., J.B., J.A., D.W., L.N., E.G., D.B.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (L.B., D.B.); Merck Research Laboratories, Merck and Company, West Point, Pennsylvania (R.B., A.C., J.L.E., R.H.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (A.J.S., S.I., D.B.); and Sunovion Inc., Marlborough, Massachusetts (S.S., G.M.)
Pei-Ching Chang
Imaging Consortium for Drug Development (L.B., J.U., P.-C.C., J.B., J.A., R.B., A.J.S., A.C., D.W., L.N., E.G., G.M., S.S., S.I., J.L.E., D.B., R.H., D.B.), P.A.I.N. Group, Children’s Hospital of Boston, Waltham, Massachusetts (L.B., J.U., P.-C.C., J.B., J.A., D.W., L.N., E.G., D.B.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (L.B., D.B.); Merck Research Laboratories, Merck and Company, West Point, Pennsylvania (R.B., A.C., J.L.E., R.H.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (A.J.S., S.I., D.B.); and Sunovion Inc., Marlborough, Massachusetts (S.S., G.M.)
James Bishop
Imaging Consortium for Drug Development (L.B., J.U., P.-C.C., J.B., J.A., R.B., A.J.S., A.C., D.W., L.N., E.G., G.M., S.S., S.I., J.L.E., D.B., R.H., D.B.), P.A.I.N. Group, Children’s Hospital of Boston, Waltham, Massachusetts (L.B., J.U., P.-C.C., J.B., J.A., D.W., L.N., E.G., D.B.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (L.B., D.B.); Merck Research Laboratories, Merck and Company, West Point, Pennsylvania (R.B., A.C., J.L.E., R.H.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (A.J.S., S.I., D.B.); and Sunovion Inc., Marlborough, Massachusetts (S.S., G.M.)
Julie Anderson
Imaging Consortium for Drug Development (L.B., J.U., P.-C.C., J.B., J.A., R.B., A.J.S., A.C., D.W., L.N., E.G., G.M., S.S., S.I., J.L.E., D.B., R.H., D.B.), P.A.I.N. Group, Children’s Hospital of Boston, Waltham, Massachusetts (L.B., J.U., P.-C.C., J.B., J.A., D.W., L.N., E.G., D.B.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (L.B., D.B.); Merck Research Laboratories, Merck and Company, West Point, Pennsylvania (R.B., A.C., J.L.E., R.H.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (A.J.S., S.I., D.B.); and Sunovion Inc., Marlborough, Massachusetts (S.S., G.M.)
Richard Baumgartner
Imaging Consortium for Drug Development (L.B., J.U., P.-C.C., J.B., J.A., R.B., A.J.S., A.C., D.W., L.N., E.G., G.M., S.S., S.I., J.L.E., D.B., R.H., D.B.), P.A.I.N. Group, Children’s Hospital of Boston, Waltham, Massachusetts (L.B., J.U., P.-C.C., J.B., J.A., D.W., L.N., E.G., D.B.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (L.B., D.B.); Merck Research Laboratories, Merck and Company, West Point, Pennsylvania (R.B., A.C., J.L.E., R.H.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (A.J.S., S.I., D.B.); and Sunovion Inc., Marlborough, Massachusetts (S.S., G.M.)
Adam J. Schwarz
Imaging Consortium for Drug Development (L.B., J.U., P.-C.C., J.B., J.A., R.B., A.J.S., A.C., D.W., L.N., E.G., G.M., S.S., S.I., J.L.E., D.B., R.H., D.B.), P.A.I.N. Group, Children’s Hospital of Boston, Waltham, Massachusetts (L.B., J.U., P.-C.C., J.B., J.A., D.W., L.N., E.G., D.B.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (L.B., D.B.); Merck Research Laboratories, Merck and Company, West Point, Pennsylvania (R.B., A.C., J.L.E., R.H.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (A.J.S., S.I., D.B.); and Sunovion Inc., Marlborough, Massachusetts (S.S., G.M.)
Alexandre Coimbra
Imaging Consortium for Drug Development (L.B., J.U., P.-C.C., J.B., J.A., R.B., A.J.S., A.C., D.W., L.N., E.G., G.M., S.S., S.I., J.L.E., D.B., R.H., D.B.), P.A.I.N. Group, Children’s Hospital of Boston, Waltham, Massachusetts (L.B., J.U., P.-C.C., J.B., J.A., D.W., L.N., E.G., D.B.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (L.B., D.B.); Merck Research Laboratories, Merck and Company, West Point, Pennsylvania (R.B., A.C., J.L.E., R.H.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (A.J.S., S.I., D.B.); and Sunovion Inc., Marlborough, Massachusetts (S.S., G.M.)
Diana Wallin
Imaging Consortium for Drug Development (L.B., J.U., P.-C.C., J.B., J.A., R.B., A.J.S., A.C., D.W., L.N., E.G., G.M., S.S., S.I., J.L.E., D.B., R.H., D.B.), P.A.I.N. Group, Children’s Hospital of Boston, Waltham, Massachusetts (L.B., J.U., P.-C.C., J.B., J.A., D.W., L.N., E.G., D.B.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (L.B., D.B.); Merck Research Laboratories, Merck and Company, West Point, Pennsylvania (R.B., A.C., J.L.E., R.H.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (A.J.S., S.I., D.B.); and Sunovion Inc., Marlborough, Massachusetts (S.S., G.M.)
Lauren Nutile
Imaging Consortium for Drug Development (L.B., J.U., P.-C.C., J.B., J.A., R.B., A.J.S., A.C., D.W., L.N., E.G., G.M., S.S., S.I., J.L.E., D.B., R.H., D.B.), P.A.I.N. Group, Children’s Hospital of Boston, Waltham, Massachusetts (L.B., J.U., P.-C.C., J.B., J.A., D.W., L.N., E.G., D.B.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (L.B., D.B.); Merck Research Laboratories, Merck and Company, West Point, Pennsylvania (R.B., A.C., J.L.E., R.H.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (A.J.S., S.I., D.B.); and Sunovion Inc., Marlborough, Massachusetts (S.S., G.M.)
Edward George
Imaging Consortium for Drug Development (L.B., J.U., P.-C.C., J.B., J.A., R.B., A.J.S., A.C., D.W., L.N., E.G., G.M., S.S., S.I., J.L.E., D.B., R.H., D.B.), P.A.I.N. Group, Children’s Hospital of Boston, Waltham, Massachusetts (L.B., J.U., P.-C.C., J.B., J.A., D.W., L.N., E.G., D.B.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (L.B., D.B.); Merck Research Laboratories, Merck and Company, West Point, Pennsylvania (R.B., A.C., J.L.E., R.H.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (A.J.S., S.I., D.B.); and Sunovion Inc., Marlborough, Massachusetts (S.S., G.M.)
Gary Maier
Imaging Consortium for Drug Development (L.B., J.U., P.-C.C., J.B., J.A., R.B., A.J.S., A.C., D.W., L.N., E.G., G.M., S.S., S.I., J.L.E., D.B., R.H., D.B.), P.A.I.N. Group, Children’s Hospital of Boston, Waltham, Massachusetts (L.B., J.U., P.-C.C., J.B., J.A., D.W., L.N., E.G., D.B.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (L.B., D.B.); Merck Research Laboratories, Merck and Company, West Point, Pennsylvania (R.B., A.C., J.L.E., R.H.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (A.J.S., S.I., D.B.); and Sunovion Inc., Marlborough, Massachusetts (S.S., G.M.)
Soujanya Sunkaraneni
Imaging Consortium for Drug Development (L.B., J.U., P.-C.C., J.B., J.A., R.B., A.J.S., A.C., D.W., L.N., E.G., G.M., S.S., S.I., J.L.E., D.B., R.H., D.B.), P.A.I.N. Group, Children’s Hospital of Boston, Waltham, Massachusetts (L.B., J.U., P.-C.C., J.B., J.A., D.W., L.N., E.G., D.B.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (L.B., D.B.); Merck Research Laboratories, Merck and Company, West Point, Pennsylvania (R.B., A.C., J.L.E., R.H.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (A.J.S., S.I., D.B.); and Sunovion Inc., Marlborough, Massachusetts (S.S., G.M.)
Smriti Iyengar
Imaging Consortium for Drug Development (L.B., J.U., P.-C.C., J.B., J.A., R.B., A.J.S., A.C., D.W., L.N., E.G., G.M., S.S., S.I., J.L.E., D.B., R.H., D.B.), P.A.I.N. Group, Children’s Hospital of Boston, Waltham, Massachusetts (L.B., J.U., P.-C.C., J.B., J.A., D.W., L.N., E.G., D.B.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (L.B., D.B.); Merck Research Laboratories, Merck and Company, West Point, Pennsylvania (R.B., A.C., J.L.E., R.H.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (A.J.S., S.I., D.B.); and Sunovion Inc., Marlborough, Massachusetts (S.S., G.M.)
Jeffrey L. Evelhoch
Imaging Consortium for Drug Development (L.B., J.U., P.-C.C., J.B., J.A., R.B., A.J.S., A.C., D.W., L.N., E.G., G.M., S.S., S.I., J.L.E., D.B., R.H., D.B.), P.A.I.N. Group, Children’s Hospital of Boston, Waltham, Massachusetts (L.B., J.U., P.-C.C., J.B., J.A., D.W., L.N., E.G., D.B.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (L.B., D.B.); Merck Research Laboratories, Merck and Company, West Point, Pennsylvania (R.B., A.C., J.L.E., R.H.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (A.J.S., S.I., D.B.); and Sunovion Inc., Marlborough, Massachusetts (S.S., G.M.)
David Bleakman
Imaging Consortium for Drug Development (L.B., J.U., P.-C.C., J.B., J.A., R.B., A.J.S., A.C., D.W., L.N., E.G., G.M., S.S., S.I., J.L.E., D.B., R.H., D.B.), P.A.I.N. Group, Children’s Hospital of Boston, Waltham, Massachusetts (L.B., J.U., P.-C.C., J.B., J.A., D.W., L.N., E.G., D.B.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (L.B., D.B.); Merck Research Laboratories, Merck and Company, West Point, Pennsylvania (R.B., A.C., J.L.E., R.H.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (A.J.S., S.I., D.B.); and Sunovion Inc., Marlborough, Massachusetts (S.S., G.M.)
Richard Hargreaves
Imaging Consortium for Drug Development (L.B., J.U., P.-C.C., J.B., J.A., R.B., A.J.S., A.C., D.W., L.N., E.G., G.M., S.S., S.I., J.L.E., D.B., R.H., D.B.), P.A.I.N. Group, Children’s Hospital of Boston, Waltham, Massachusetts (L.B., J.U., P.-C.C., J.B., J.A., D.W., L.N., E.G., D.B.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (L.B., D.B.); Merck Research Laboratories, Merck and Company, West Point, Pennsylvania (R.B., A.C., J.L.E., R.H.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (A.J.S., S.I., D.B.); and Sunovion Inc., Marlborough, Massachusetts (S.S., G.M.)
David Borsook
Imaging Consortium for Drug Development (L.B., J.U., P.-C.C., J.B., J.A., R.B., A.J.S., A.C., D.W., L.N., E.G., G.M., S.S., S.I., J.L.E., D.B., R.H., D.B.), P.A.I.N. Group, Children’s Hospital of Boston, Waltham, Massachusetts (L.B., J.U., P.-C.C., J.B., J.A., D.W., L.N., E.G., D.B.); Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (L.B., D.B.); Merck Research Laboratories, Merck and Company, West Point, Pennsylvania (R.B., A.C., J.L.E., R.H.); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (A.J.S., S.I., D.B.); and Sunovion Inc., Marlborough, Massachusetts (S.S., G.M.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleDrug Discovery and Translational Medicine
Translation of the Buprenorphine PhMRI Response
Lino Becerra, Jaymin Upadhyay, Pei-Ching Chang, James Bishop, Julie Anderson, Richard Baumgartner, Adam J. Schwarz, Alexandre Coimbra, Diana Wallin, Lauren Nutile, Edward George, Gary Maier, Soujanya Sunkaraneni, Smriti Iyengar, Jeffrey L. Evelhoch, David Bleakman, Richard Hargreaves and David Borsook
Journal of Pharmacology and Experimental Therapeutics April 1, 2013, 345 (1) 41-51; DOI: https://doi.org/10.1124/jpet.112.201145
Research ArticleDrug Discovery and Translational Medicine
Translation of the Buprenorphine PhMRI Response
Lino Becerra, Jaymin Upadhyay, Pei-Ching Chang, James Bishop, Julie Anderson, Richard Baumgartner, Adam J. Schwarz, Alexandre Coimbra, Diana Wallin, Lauren Nutile, Edward George, Gary Maier, Soujanya Sunkaraneni, Smriti Iyengar, Jeffrey L. Evelhoch, David Bleakman, Richard Hargreaves and David Borsook
Journal of Pharmacology and Experimental Therapeutics April 1, 2013, 345 (1) 41-51; DOI: https://doi.org/10.1124/jpet.112.201145
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement